30 active not recruiting, 20 completed, 11 terminated, 10 recruiting. 41 Phase 2, 31 Phase 1, 13 Not applicable, 3 Early Phase 1, 2 Phase 3.
Follow Stage IVA Lung Cancer AJCC v8: new trials by email Literature Review of Stage IVA Lung Cancer AJCC v8 trials Research Report on Stage IVA Lung Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial Carboplatin, Cisplatin, Durvalumab - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Withdrawn | University of Washington | 2023-10-19 | 2023-10-18 | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer EMB-01, Osimertinib - Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Shanghai EpimAb Biotherapeutics Co., Ltd. | 115 | 2023-06-01 | 2023-06-01 |
| Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | University of Southern California | 5 | 2022-12-07 | 2026-01-29 |
| PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Recruiting | Dwight Owen | 30 | 2022-11-21 | 2026-02-06 |
| Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Aldesleukin, Pembrolizumab - Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Early Phase 1 | Recruiting | Emory University | 15 | 2022-11-01 | 2026-02-12 |
| Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue Exercise Counseling, Exercise Intervention, Internet-Based Intervention - Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Not applicable | Terminated | Mayo Clinic | 7 | 2022-08-17 | 2025-02-07 |
| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Carboplatin, Pemetrexed, Selpercatinib - Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2022-07-25 | 2024-07-09 | |
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | University of California, Irvine | 6 | 2022-07-20 | 2026-10-06 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial Best Practice, Exercise Intervention, Physical Therapy - Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 100 | 2022-04-14 | 2025-11-21 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer Health Education, Questionnaire Administration - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Not applicable | Active not recruiting | Ohio State University Comprehensive Cancer Center | 243 | 2022-03-30 | 2026-10-22 |
| Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Cobalamin, Dexamethasone, Docetaxel - Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | SWOG Cancer Research Network | 82 | 2022-03-15 | 2026-05-18 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer Biopsy, Osimertinib, Triptolide Analog - Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2022-03-07 | 2026-03-05 |
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer Aurora A Kinase Inhibitor LY3295668, Osimertinib - Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2022-02-17 | 2026-09-18 |
| Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer Atezolizumab, Temozolomide - Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 2 | Recruiting | Dwight Owen | 56 | 2022-01-26 | 2026-04-08 |
| Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer Osimertinib, Tegavivint, Echocardiography Test - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 25 | 2022-01-18 | 2026-09-15 |
| All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Tretinoin - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | Dwight Owen | 18 | 2021-10-18 | 2026-07-20 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer Bintrafusp Alfa, Pemetrexed, Carboplatin - Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2021-06-30 | 2023-08-01 |
| Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer Poziotinib Hydrochloride, 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-06-16 | 2023-09-13 |
Showing 20 of 80. Sign in to see all of them.
Lung Neoplasms (80) · Carcinoma, Non-Small-Cell Lung (47) · Melanoma (7) · Neoplasm Metastasis (7) · Brain Neoplasms (5) · Colorectal Neoplasms (5) · Small Cell Lung Carcinoma (5) · Carcinoma, Renal Cell (4) · Breast Neoplasms (3) · Ovarian Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Adenocarcinoma of Lung (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2)
Lung Diseases (80) · Neoplasms (80) · Neoplasms by Site (80) · Respiratory Tract Diseases (80) · Respiratory Tract Neoplasms (80) · Thoracic Neoplasms (80) · Bronchial Neoplasms (51) · Carcinoma, Bronchogenic (51) · Neoplasms by Histologic Type (14) · Digestive System Diseases (10) · Carcinoma (9) · Digestive System Neoplasms (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms, Glandular and Epithelial (9)
pembrolizumab (12) · Immunoglobulin G (11) · Disulfides (10) · Carboplatin (9) · Nivolumab (8) · Pemetrexed (8) · osimertinib (8) · atezolizumab (6) · durvalumab (6) · Docetaxel (5) · Ramucirumab (5) · Early Intervention, Educational (4) · Educational Status (4) · Methods (4) · Radiation (4)
M.D. Anderson Cancer Center (26) · Ohio State University Comprehensive Cancer Center (8) · SWOG Cancer Research Network (8) · City of Hope Medical Center (5) · National Cancer Institute (NCI) (5) · Emory University (4) · Dwight Owen (3) · Jonsson Comprehensive Cancer Center (3) · Mayo Clinic (3) · Roswell Park Cancer Institute (2) · University of Southern California (2) · Wake Forest University Health Sciences (2) · OHSU Knight Cancer Institute (1) · Rahul Aggarwal (1) · Rutgers, The State University of New Jersey (1)
United States (75) · China (1) · Guam (1) · Puerto Rico (1)
Yasir Y Elamin, MD (3) · Jonathan W Goldman (2) · Jonathan W Riess (2) · Kathrin Milbury (2) · Xiuning Le (2) · Yasir Y Elamin (2) · Anne Reb (1) · Anurag K Singh (1) · Arya Amini (1) · Asrar Alahmadi, MBBS, MAS-CR (1) · Aung Naing, MD (1) · Badi El Osta, MD, FACP (1) · Barbara Andersen, PhD (1) · Betty Ferrell (1) · Carolyn J Presley, MD (1)
PMID 33909232, PMID 34036820, PMID 34562230, PMID 34663123, PMID 34965890, PMID 35537412, PMID 37129197, PMID 37328287, PMID 38106014, PMID 38197040, PMID 38572955, PMID 39816915, PMID 39886125, PMID 39903538, PMID 39945382, PMID 40580957, PMID 42830627, PMID 42868120
U10CA180888 (8), P30CA033572 (5), P30CA138292 (4), P30CA012197 (2), P30CA014089 (2), UM1CA186691 (2), K08CA245249 (1), K76AG074923 (1), P30CA016672 (1), P30CA060553 (1), P30CA072720 (1), P30CA093373 (1), P50CA217691 (1), R01CA155196 (1), R01CA248741 (1)